Cardiac dysrhythmias are common during bronchoscopy, and the incidence does not vary greatly with the method of general or local anaesthesia (Burman and Gibson, 1963; Van Nouhuys, 1965; Jenkins, 1966) .
The commonest abnormalities of cardiac function that occur are tachycardia (sinus or nodal), and varying forms of extrasystole, nodal and ventricular ectopic beats being fairly common. Multifocal ventricular extrasystoles do not often occur but are usually regarded as being of more serious significance.
A reduction in the frequency of dysrhythmias was claimed by Koster and Nielsen (1968) using the ventilating bronchoscope, although in their series also the incidence was as high as 14 per cent. Pender and his colleagues (1968) showed that whereas arterial carbon dioxide tension (Paoo 2 ) rose, and pH fell during most forms of anaesthesia for bronchoscopy, the Pac 03 fell and the pH rose during use of the ventilating bronchoscope. These findings appear to support the view previously expressed (Jenkins, 1966 ) that dysrhythmias arise in part as a result of rise in arterial carbon dioxide tension, with consequent increase in circulating catecholamines.
In these circumstances, the trial of an adrenergic beta-blocking agent appeared to be justifiable during bronchoscopy, the aim being to reduce or abolish dysrhythmia and undesirable tachycardia. Propranolol was, at first, used in a few patients. The results were promising but it was felt that the danger of producing a severe increase in airway resistance in these patients was excessive.
ICI 50,172 is a new beta-adrenergic blocking agent which has been shown in animals and in man to produce minimal increase in airway resistance whilst retaining blocking effect upon cardiac receptors. It is effective within 1 minute of intravenous injection, and a dose of 20 mg retains its effect for at least half an hour (Johnstone, 1969) . This new drug was therefore given i.v. to thirtythree patients who developed excessive tachycardia or cardiac dysrhythmia during bronchoscopy.
MATERIAL AND METHODS
The patients were mostly in-patients or outpatients requiring diagnostic bronchoscopy for suspected bronchial carcinoma. Two patients required therapeutic bronchoscopy for sputum retention or atelectasis. All patients had been examined and fully assessed, either at a chest clinic or as in-patients. No patient had been diagnosed as suffering from established heart disease, although two male patients were found at bronchoscopy to exhibit left bundle branch block (LBBB) on the control electrocardiographic (e.c.g.) tracing. Many of the patients suffered from moderately severe chronic bronchitis and A. VIVIAN JENKINS, M.R, F.FjUtcs., Department of Anaesthetics, East Birmingham Hospital, Birmingham 9. emphysema, and showed some evidence of actual airways obstruction at the time of bronchoscopy. During the period of the clinical trial the proportion of patients who were given ICI 50,172 was about 20 per cent of all those subjected to bronchoscopy.
Routine six-lead e.c.g. was recorded on each patient (no chest leads), recordings being taken after premedication but before anaesthesia. During bronchoscopy e.c.g. lead II was monitored continuously by oscilloscope and recordings were made of any abnormality. Repeated estimation of blood pressure by sphygmomanometry was abandoned after the first six cases, when no change in pressure could be detected following the injection of ICI 50,172.
The anaesthetic technique was a modification of that first described by Cheatle and Chambers (1955) . Oxygen was insufflated continuously through a fine catheter which terminated at the level of the carina, general anaesthesia being maintained by intermittent injections of thiopentone, and apnoea and muscle relaxation by intermittent doses of suxamethonium. All patients received premedication of atropine 0.6 mg and morphine 10 mg intramuscularly \ to 1 hour before bronchoscopy.
ICI 50,172 was administered to thirty-three patients (table I). In most cases the indication was an increasing tachycardia, sometimes accompanied by other signs of sympathetic hypertonus such as marked sweating. Some of these patients developed, in addition, a cardiac dysrhythmia. Two patients became dysrhythmic in the absence of tachycardia.
There was some difficulty in defining the precise indications for ICI 50,172 administration in these patients. Tachycardia of moderate degree is obviously not a dangerous condition, but in the presence of coronary insufficiency an increasing heart rate becomes undesirable due to the shortness of the diastolic pause and the greatly increased oxygen demands of the myocardium. At the commencement of the investigation a heart rate exceeding 150 beats/min was taken as an indication for the use of ICI 50,172, earlier work (Jenkins, 1966) having shown this to be the degree of tachycardia at which dysrhythmia becomes more likely to develop. Later, when the relative safety of the drug under these conditions became more obvious, the figure was lowered to 125 beats/min, the object then being to reduce the rate to approximately 100 beats/min.
There was greater difficulty with those patients who developed dysrhythmia in the absence of progressive tachycardia, since the dysrhythmic state may be quite transient during bronchoscopy and may be followed by long periods of sinus rhythm It was finally decided to use the drug only if a continuous period of dysrhythmia of at least 15 seconds had occurred.
Dosage.
This commenced in the first patient at 10 mg Lv. given over a period of about 10 seconds, and repeated in 2 minutes if the desired effect was not obtained. This was later increased to 20 mg i.v. as the first dose and repeated up to a total of 60 mg over a period of 8-10 minutes. In the two patients exhibiting LBBB the initial dose was restricted to 10 mg.
RESULTS (TABLE II)
The "control" rate was obtained from the e.cg. prior to anaesthesia; the "initial" rate was that at which the first injection of ICI 50,172 was made. It usually indicated the tachycardia that justified the use of the drug, but in two patients although the heart rate remained normal there was a development of dysrhythmia. The "final" rate refers to the lowest rate noted after injection. "Duration" refers to the period during which continuous observation of the patient was maintained throughout the bronchoscopy and following the injection of ICI 50,172. Many patients were intermittently observed in recovery areas for much longer periods. No further slowing of the pulse was noted during this period.
In no patient was there any clinically detectable increase in airways resistance. There were no observable effects upon the blood pressure in those cases where it was monitored, or other circulatory changes. Apart from the changes described, there were no other changes in the e.c.g. that could be ascribed to ICI 50,172 ( figs. 1, 2, 3, 4) .
A satisfactory reduction in heart rate was achieved in every case, although it was not always possible with the dosage used to achieve a rate below 100 beats/min. The maip fall in rate occurred within 1 minute of injection, although there was usually some further slight fall in the course of the next 2-3 minutes. Once the rate had decreased to less than 100 beats/min, further injections of ICI 50,172 had much less effect or no effect at all.
When the tachycardia was accompanied by dysrhythmia, the abnormal rhythm was usually abolished on reducing the heart rate. In three patients, however, the dysrhythmia, although improved, was not abolished. 
DISCUSSION
It was suggested in a previous publication (Jenkins, 1966 ) that the observed changes in the electrocardiogram during bronchoscopy are probably mediated partly by vagal afferent and efferent fibres, partly by variation in the tone of the cardio-accelerator fibres of the sympathetic, and partly by increase in the catecholamine levels in the plasma and in the heart itself. It was presumed that the increase in catecholamines is the result of apprehension on the part of the patient, combined with some diminution in arterial oxygen tension (Pao 3 ) and elevation in arterial carbon dioxide tension. The use of a beta-adrenergic blocking agent to reverse tachycardia and dysrhythmia due to this specific factor would thus seem to be logical. Propranolol has become established as a powerful beta-adrenergic blocking agent with action on the cardiac beta-receptors (Harris et al., 1966) . It has been used in the treatment of cardiac dysrhythmias during anaesthesia (Johnstone, 1966) and in a wide variety of cardiovascular conditions (Rowlands, Howitt and Markman, 1965; Sloman, Robinson and McLean, 1965) . Although it is effective in abolishing dysrhythmias and in slowing heart rate, it also causes increased airways resistance (McNeill, 1964; McNeill and Ingram, 1966; Macdonald, Ingram and McNeill, 1967) , and reduces both the ejection rate and the velocity of ventricular contraction (Hamer, Fleming and Shinebourne, 1968) . ICI 50,172 is a new beta-blocking drug which also has powerful effects upon the cardiac beta-receptors but which does not diminish cardiac contractile force (Dunlop and Shanks, 1968; Gibson and Sowton, 1968) . Its effect on airways resistance is minimal and it can safely be given to asthmatic patients (Macdonald and McNeill, 1968) .
In the present investigation, 10 50,172 was found to be effective in every patient in reducing heart rate. It was rather less effective in abolishing dysrhythmia, although the impression was gained that when the heart rate was slowed, the dysrhythmic tendency was diminished. The mechanism of dysrhythmia in the presence of catecholamine excess is complex, and beta-blockade would not be expected to succeed in every case, particularly as ICI 50,172 does not possess the local anaesthetic and quinidine-like properties of propranoloL Tachycardia would not normally be regarded as hazardous in the average patient, since heart rates approaching 200 beats/min occur during violent exertion in reasonably fit people. On the other hand, the patients in this investigation were nearly all in the age group where undiagnosed coronary insufficiency might be expected occasionally to exist. Indeed, in two of the thirty-three patients there was electrocardiographic evidence of left bundle branch block, although careful clinical examination had shown no more than moderate arterial hypertension. In these circumstances, severe tachycardia can provoke congestive heart failure as a result of cardiac overwork and fatigue from inadequate diastolic rest (Wood, 1968) . In the same way, severe dysrhythmia may result in hypotension with diminution in coronary flow and in myocardial oxygenation.
ICI 50,172 was found to be an effective agent for beta-adrenergic blockade during bronchoscopy. It is in many ways a more suitable drug than propranolol, in so far as it does not reduce myocardial contractile force and is not a depressant of the cardiac conducting tissue. The fact that it has no tendency to increase airways resistance makes it a better choice in broncbitic and asthmatic patients, who are more likely to present for bronchoscopy. a similar volume of colloid replacement down to a haemoglobin level of 2.8 g%. Under these conditions, the animal* receiving gelatin uniformly died, while those receiving a dextran (mean moL wt., 70,000) survived. The difference could, however, be entirely due to the fact that the latter preparation is slighdy hyperoncotic, and therefore not only would the circulatory condition be better-with regard to filling volume-but, because of haemodilution, a comparable haemoglobin level would be achieved when less red cells had been shed. Section V is on rheology, and is remarkable for the uniformity with which the various authors agree that stasis causes sludging, and not the other way round, and that low molecular weight dextrans exert their effect chiefly by dilution, and not by any specific disaggregating property. Indeed, these preparations actually increase viscosity if haanatocrit is kept constant.
Sections VI-VII, which deal with kidney function and coagulation, convey the message that gelatins have less undesirable side effects than dextrans; Section VIII is devoted to experiences of other uses of gelatins in various special situations, such as extracorporeal circulation, and as vitreous replacement; and Section IX is concerned with stability in storage.
Although nominally about gelatins, in nearly every paprr there is comparative work with dextrans, and often-where appropriate-with plasma, or electrolyte infusions. This immeasurably extends the value of this book.
There is, of course, much more in a book such as this than any individual reader needs, whether his needs are educational or research. Despite the inevitable two-year delay, the material seems remarkably up to date. It contains the entree to the whole field, either directly, or via references, although-inevitably-many of these are not in English, and would bi invaluable to anyone taking up, or already working in, any of the related fields of research.
It is unlikely to be significantly out of date for several years and, therefore, would be a useful purchase for University Libraries, and, at 150s., not disproportionately expensive as a reference source.
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